2021 Service Expansions: Microsomal Protein Binding and Red Blood Cell Partitioning

Over the course of 2021, we expanded access to two important and related study offerings at our US laboratory headquarters. Although plasma protein binding was already available at this location, we added access to Red Blood Cell Partitioning service for improved pharmacokinetics assessments and Microsomal Protein Binding for DMPK profile development and DDI assessment of new drugs.

Pharmacokinetic (PK) parameters of new drug candidates are traditionally determined by measuring drug concentration in plasma. However, many compounds bind to or diffuse into red blood cells (RBCs), and considering RBCs comprise at least 99% of cellular space in blood, this can significantly impact clearance and cause inaccuracies in PK calculations. Learn more.

We also added Microsomal Protein Binding to similarly help customers more easily investigate how much of their drug will be available to bestow its intended therapeutic effect in the presence of microsomes. Learn more.

Read the Red Blood Cell Partitioning Service Expansion Press Release
Read the Microsomal Protein Binding Service Expansion Press Release